

A randomised double-blind trial in post-menopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 19/10/2017	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr RE Coleman

Contact details
Academic Unit of Clinical Oncology
Cancer Research Centre
Weston Park Hospital
Sheffield
United Kingdom
S10 2RX
+44 (0)114 271 3518
R.E.Coleman@sheffield.ac.uk

Additional identifiers

Protocol serial number
960EXE031

Study information

Scientific Title

A randomised double-blind trial in post-menopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen

Study objectives

Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, little information exists on the long-term effects of aromatase inhibitors after treatment, and whether these early improvements lead to real gains in survival.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double-blind controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

1. Patients in the reference arm will receive an overall course of tamoxifen for 5 years (20 mg /day)
2. Patients in the investigational arm will receive 25 mg/day exemestane (after 2-3 years tamoxifen giving a total of 5 years endocrine therapy)

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tamoxifen, exemestane

Primary outcome(s)

Disease-free survival

Key secondary outcome(s)

Overall survival

Completion date

31/12/2003

Eligibility**Key inclusion criteria**

1. Histologically/cytologically confirmed unilateral operable breast adenocarcinoma
2. Estrogen receptor (ER)+ or ER unknown
3. Adequate therapy for primary disease
4. Postmenopausal
5. Receiving tamoxifen and treated with tamoxifen for 2-3 years
6. Remain free from disease following treatment for primary disease

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

31/12/2003

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Weston Park Hospital
Sheffield
United Kingdom
S10 2RX

Sponsor information

Organisation

Pharmacia Ltd & Upjohn (UK)

ROR

<https://ror.org/04x4v8p40>

Funder(s)

Funder type

Industry

Funder Name

Pharmacia and Upjohn (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results of the 2nd interim analysis of efficacy	11/03/2004		Yes	No
Results article	survival and safety results	17/02/2007		Yes	No
Results article	5-year follow-up study results	13/03/2012		Yes	No
Results article	long-term follow-up results	01/08/2017		Yes	No
Other publications	retrospective analysis	01/04/2012		Yes	No